advertisement
Tomita G 13
Showing records 1 to 13 | Display all abstracts from Tomita G99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Inoue K
American Journal of Ophthalmology 2022; 237: 114-121
100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Inoue K; Shiokawa M
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Shiokawa M
American Journal of Ophthalmology 2022; 237: 114-121
100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Kunimatsu-Sanuki S
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Katakura S
American Journal of Ophthalmology 2022; 237: 114-121
100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Nozaki N
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Tsuruoka M; Kunimatsu-Sanuki S
American Journal of Ophthalmology 2022; 237: 114-121
100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Shimizu K
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Shimizu K
American Journal of Ophthalmology 2022; 237: 114-121
100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Ishida K
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Ishida K
American Journal of Ophthalmology 2022; 237: 114-121
100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Tomita G
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Tomita G
American Journal of Ophthalmology 2022; 237: 114-121
